Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects with Intermediate-Risk (sub-massive) Acute Pulmonary Embolism (PE)
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs TS 23 (Primary)
- Indications Pulmonary embolism
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 21 Nov 2017 This trial has been Discontinued Hungary.
- 14 Nov 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 Aug 2017 New trial record